The FDA approval of 5 new therapeutic agents within a 4-year time frame, all of which potentially improve survival for patients with metastatic castration-resistant prostate cancer, is unprecedented in oncology.
The diversity of the mechanisms of action of these agents is compelling, including the first and only therapeutic cancer vaccine, the first approved use of an alpha emitter, 2 novel next generation hormonal therapy agents, and a second-generation taxane. However, with this therapeutic bounty comes new challenges in the optimal use of these new and expensive agents in a disease well known for its heterogeneity.
Written by:
Dreicer R. Are you the author?
Reference: Am J Manag Care. 2014 Dec;20(11 Suppl):s282-9.
PubMed Abstract
PMID: 25734964